Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

Journal of Hepatology
Harry L A JanssenEdward J Gane

Abstract

Vesatolimod (GS-9620) is an oral agonist of toll-like receptor 7, an activator of innate and adaptive immune responses. Herein the safety and efficacy of vesatolimod is assessed after once-weekly treatment in patients with chronic hepatitis B (CHB) infection suppressed on oral antiviral treatment. In a phase II, double-blind, randomized, placebo (PBO)-controlled study, 162 patients stratified by hepatitis B surface antigen (HBsAg) levels and serum hepatitis B e antigen (HBeAg) status were randomized 1:3:3:3 to once-weekly oral PBO or vesatolimod (1-, 2-, or 4-mg doses) for 4, 8 or 12 weeks per cohort. Efficacy was assessed by change in baseline HBsAg (log10 IU/ml) at the primary endpoint (Week 24). Safety assessments included adverse events (AE) and laboratory abnormality monitoring. Pharmacodynamic assessments included peripheral cytokine level quantification and interferon-stimulated gene (ISG) mRNA expression evaluation. The majority of patients were male (76%) and HBeAg-negative (79%) at baseline. Most (41-80%) experienced ≥1 AE during the study with the majority of AEs mild or moderate in severity. No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48). ISG15...Continue Reading

Citations

Oct 21, 2018·Medicinal Research Reviews·Violeta Carmona-MartínezPilar García-Peñarrubia
Nov 20, 2018·Medicinal Research Reviews·Muhammad Ayaz AnwarSangdun Choi
Nov 28, 2018·Journal of Leukocyte Biology·Lauke L BoeijenAndré Boonstra
Feb 17, 2019·Journal of Viral Hepatitis·Cihan Yurdaydin
Nov 26, 2019·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Sun Hong Yoo, Jung Hyun Kwon
May 12, 2019·Current Treatment Options in Gastroenterology·Hannah M Lee, Bubu A Banini
Nov 13, 2019·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Markus CornbergUNKNOWN 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty
Apr 21, 2018·Frontiers in Microbiology·Alireza MohebbiAlijan Tabarraei
Jun 8, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Zobair M YounossiFatema Nader
Sep 14, 2018·World Journal of Clinical Cases·Jian TangGuo-Zhong Gong
Sep 12, 2019·International Journal of Environmental Research and Public Health·Laura Ambra NicoliniLaura Sticchi
Oct 9, 2019·Hepatology Communications·Antonio Bertoletti, Nina Le Bert
May 28, 2020·Frontiers in Cellular and Infection Microbiology·Shokichi Takahama, Takuya Yamamoto
Sep 19, 2020·Microorganisms·Magda Rybicka, Krzysztof Piotr Bielawski
Sep 25, 2019·Nature Reviews. Gastroenterology & Hepatology·Mala K Maini, Alice R Burton
Oct 9, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ming-Lun YehWan-Long Chuang
May 18, 2018·Nature Reviews. Microbiology·Yi-Chieh Perng, Deborah J Lenschow
Sep 26, 2020·Future Science OA·Livia OnofrioCarlo Buonerba
Oct 7, 2020·Journal of Clinical Medicine·Alexandra AlexopoulouPeter Karayiannis
Oct 13, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sharon A RiddlerDevi SenGupta
Oct 22, 2020·Annual Review of Medicine·Susanna Naggie, Anna S Lok
Jan 1, 2021·International Journal of Molecular Sciences·Hye Won LeeSang Hoon Ahn
Jan 1, 2021·Frontiers in Immunology·Ying Cai, Wenwei Yin
Mar 24, 2020·European Journal of Medicinal Chemistry·Cindy PatinoteCarine Deleuze-Masquéfa
Mar 9, 2021·Expert Opinion on Drug Discovery·Xuan HuangMengji Lu
Oct 15, 2020·Expert Opinion on Therapeutic Patents·Madeleine E KiefferW Michael Seganish
Oct 28, 2018·Gastroenterology·Adam J Gehring, Ulrike Protzer
Mar 21, 2021·Clinical and Translational Science·Joseph F GrippoElizabeth Calleja
Apr 15, 2019·The Lancet. Gastroenterology & Hepatology·Peter A RevillFabien Zoulim
May 23, 2021·Reviews in Medical Virology·Forough Golsaz-Shirazi, Fazel Shokri
Jun 2, 2021·The Journal of Clinical Investigation·Tsung-Yu TsaiShie-Liang Hsieh
May 17, 2021·Current Opinion in Virology·Carolina ChialeMichael D Robek
Jun 3, 2021·Pharmaceuticals·Georgia-Myrto PriftiGrigoris Zoidis
Dec 29, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Oliver E AminLaura J Pallett
Jun 23, 2021·Liver International : Official Journal of the International Association for the Study of the Liver·Armando Andres Roca SuarezFabien Zoulim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.